FTD/TPI治疗转移性结直肠癌中性粒细胞减少与生存结局
本文基于II期J003和III期RECOURSE试验的事后分析,探讨FTD/TPI暴露与化疗诱导中性粒细胞减少(CIN)及临床结局的关系。RECOURSE子集210例患者中,高FTD AUC组CIN风险显著增加;全人群分析显示,发生CIN的患者OS和PFS显著优于未发生CIN者及安慰剂组,J003队列验证了该结果。
要点
- 高FTD暴露与CIN风险增加相关
- 发生CIN者OS和PFS显著优于未发生者及安慰剂组
- CIN或可作为FTD/TPI疗效预测指标
核心结论
- FTD/TPI治疗转移性结直肠癌患者中,发生化疗诱导中性粒细胞减少(CIN)与更长的OS和PFS相关。
研究设计与样本
- 基于II期J003(N=169)和III期RECOURSE(N=800)试验的事后分析,RECOURSE子集210例患者进行有限采样药代动力学分析。
主要发现
- RECOURSE子集中,高FTD AUC组CIN风险显著增加。
- 全人群分析显示,FTD/TPI治疗患者第1和2周期发生任何级别CIN者中位OS和PFS显著长于未发生CIN者及安慰剂组。
- 需要延迟FTD/TPI治疗的患者OS和PFS优于安慰剂组及未发生CIN者。
- J003队列获得相似结果。
临床怎么用
- CIN的发生可能作为FTD/TPI治疗转移性结直肠癌患者结局的预测指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer. This post hoc analysis investigated pharmacokinetic data of FTD/TPI exposure and pharmacodynamic markers, such as chemotherapy-induced neutropenia (CIN) and clinical outcomes. PATIENTS AND METHODS: A total of 210 patients from RECOURSE were enrolled in this substudy. A limited sampling approach was used, with three pharmacokinetic samples drawn on day 12 of cycle 1. Patients were categorized as being above or below the median area under the plasma concentration-time curve (AUC) for FTD and TPI. We conducted a post hoc analysis using the entire RECOURSE population to determine the correlations between CIN and clinical outcome. We then carried out a similar analysis on the J003 trial to validate the results. RESULTS: In the RECOURSE subset, patients in the high FTD AUC group had a significantly increased CIN risk. Analyses of the entire population demonstrated that FTD/TPI-treated patients with CIN of any grade in cycles 1 and 2 had significantly longer median overall survival (OS) and progression-free survival (PFS) than patients who did not develop CIN and patients in the placebo group. Patients who required an FTD/TPI treatment delay had increased OS and PFS versus those in the placebo group and those who did not develop CIN. Similar results were obtained in the J003 cohort. CONCLUSIONS: In RECOURSE, patients with higher FTD drug exposure had an increased CIN risk. FTD/TPI-treated patients who developed CIN had improved OS and PFS versus those in the placebo group and those who did not develop CIN. Similar findings were reported in the J003 cohort, thus validating the RECOURSE results. The occurrence of CIN may be a useful predictor of treatment outcomes for FTD/TPI-treated patients. CLINICALTRIALS. GOV IDENTIFIER: NCT01607957 (RECOURSE). JAPAN PHARMACEUTICAL INFORMATION CENTER NUMBER: JapicCTI-090880 (J003).
引用
- Yoshino T, Cleary JM, Van Cutsem E, et al. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol. 2020. PMID: 31912801. doi:10.1016/j.annonc.2019.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。